Sign In
Buy ABCL
$5.80
-0.665 (-10.29%)
At Close: Jul 20, 2026
AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024
04:05pm, Thursday, 26'th Sep 2024
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024.
AbCellera: A Waiting Game With High Uncertainty
04:43am, Friday, 23'rd Aug 2024
AbCellera's Q2 2024 revenue declined by 27% year-over-year to $7.3 million. The company's net loss widened to $36.9 million due to increased R&D expenses. AbCellera's cash and marketable securities to
AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Misses Revenue Estimates
07:15pm, Tuesday, 06'th Aug 2024
AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.11 per share a year ago.
5 Penny Stocks With 250% Upside in 1 Year According to Wall Street
08:49am, Tuesday, 30'th Jul 2024
Penny stocks represent an interesting investment opportunity.
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?
05:37am, Sunday, 21'st Jul 2024
The Baker brothers acquired millions of shares of AbCellera Biologics and Fate Therapeutics during the first months of 2024. AbCellera Biologics is a drug discovery business with a hand in more than a
AbCellera Biologics (ABCL) Upgraded to Buy: Here's What You Should Know
01:01pm, Tuesday, 09'th Jul 2024
AbCellera Biologics (ABCL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024
04:05pm, Tuesday, 25'th Jun 2024
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024.
Down 57%, Is AbCellera Biologics a Buy on the Dip?
05:40am, Thursday, 13'th Jun 2024
AbCellera Biologics is a biotechnology company built to discover new antibodies for other drugmakers. The stock has fallen more than 90% from its all-time high and by 57% from a peak it set last summe
AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024
04:05pm, Tuesday, 28'th May 2024
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024.
3 Stock Gems Hiding in the Nasdaq
06:00am, Monday, 13'th May 2024
With the technology benchmark Nasdaq index encountering some choppy weather since April, speculators may want to consider undervalued Nasdaq stocks. Granted, it's always risky betting on enterprises t
AbCellera Biologics Inc. (ABCL) Q1 2024 Earnings Call Transcript
11:00pm, Tuesday, 07'th May 2024
AbCellera Biologics Inc. (NASDAQ:ABCL ) Q1 2024 Earnings Conference Call May 7, 2024 5:00 PM ET Company Participants Tryn Stimart - Chief Legal & Compliance Officer Carl Hansen - President, Chief Exec
AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates
07:06pm, Tuesday, 07'th May 2024
AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.14 per share a year ago.
AbCellera Reports Q1 2024 Business Results
04:05pm, Tuesday, 07'th May 2024
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q1 2024 Business Results.
AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies
09:00am, Wednesday, 01'st May 2024
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies.
Analysts Estimate AbCellera Biologics Inc. (ABCL) to Report a Decline in Earnings: What to Look Out for
11:06am, Tuesday, 30'th Apr 2024
AbCellera Biologics (ABCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
